<DOC>
	<DOCNO>NCT02104583</DOCNO>
	<brief_summary>This study evaluate effect eleclazine ( GS-6615 ) compare placebo overall occurrence appropriate implantable cardioverter-defibrillator ( ICD ) intervention ( antitachycardia pace [ ATP ] shock ) adult ICD cardiac resynchronization therapy-defibrillator ( CRT-D ) .</brief_summary>
	<brief_title>Evaluating Ventricular Arrhythmia Subjects With Implantable Cardioverter Defibrillator Cardiac Resynchronization Therapy-Defibrillator</brief_title>
	<detailed_description />
	<criteria>Key Have ICD CRTD implant primary secondary prevention least one ICD intervention ventricular tachycardia/ventricular fibrillation ( VT/VF ) [ shock ATP ] within 60 day prior screen document VT/VF episode ( prior implantation ) within 60 day prior screen Use highly effective contraception method female childbearing potential sexually active male Must hemodynamically stable Key New York Heart Association ( NYHA ) Class IV heart failure Myocardial infarction , unstable angina , coronary artery bypass graft ( CABG ) surgery percutaneous coronary intervention ( PCI ) within 4 week prior screen screen period randomization Hemodynamically significant primary obstructive valvular disease History congenital heart disease Inherited arrhythmia Brugada syndrome . Individuals long QT syndrome Type 3 ( LQT3 ) hypertrophic cardiomyopathy ( HCM ) may consider . Individuals consider cardiac transplantation cardiac transplant list History seizures epilepsy Cardiac ablation within 3 month prior screen plan cardiac ablation study Severe renal impairment Abnormal liver function test Currently take Class I Class III antiarrhythmic drug ; medication discontinue 5 halflives ( 28 day chronic use amiodarone ) prior randomization Currently take drug product strong inhibitor inducer CYP3A ; medication discontinue 5 halflives prior randomization Currently take ranolazine ; Ranolazine discontinue least 7 day prior Randomization Females pregnant breastfeeding Individuals subcutaneous ICD Body mass index ( BMI ) â‰¥ 36 kg/m^2 Note : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>VT</keyword>
	<keyword>VF</keyword>
	<keyword>Ventricular Tachycardia</keyword>
	<keyword>Ventricular Fibrillation</keyword>
	<keyword>shock</keyword>
	<keyword>ATP</keyword>
</DOC>